首页 / 院系成果 / 成果详情页

Evaluating Bezlotoxumab-Fidaxomicin Combination Therapy in Clostridioides Infection: A Single-Center Retrospective Study from Aichi Prefecture, Japan 期刊论文

编号：

ABD674DDC56FCF5B0F696F2F4159844B
作者：

Hirai, Jun^[1,2,3] Mori, Nobuaki^[1,2] Hanai, Yuki^[4] Asai, Nobuhiro^[1,2] Hagihara, Mao^[5] Mikamo, Hiroshige^[1,2]
语种：

英文
期刊：

ANTIBIOTICS-BASEL ISSN：2079-6382 2025 年 14 卷 3 期 ; FEB 24
关键词：

bezlotoxumab fidaxomicin combination therapy Clostridioides difficile recurrence severe diarrhea
摘要：

Background/Objectives: Clostridioides difficile infection (CDI) poses a significant healthcare challenge, with recurrence rates reaching 30%, leading to substantial morbidity and costs. Fidaxomicin (FDX) and bezlotoxumab (BEZ) have shown potential in reducing recurrence; however, real-world data on the efficacy of their combination in high-risk CDI patients remain limited. This study aimed to evaluate the efficacy and safety of FDX + BEZ compared with FDX alone in CDI patients with recurrence risk factors. Methods: CDI patients with >= two recurrence risk factors treated with FDX alone or FDX + BEZ were analyzed. Sixteen factors were evaluated as risk factors for recurrent CDI based on findings from previous studies. Patients with FDX treatment duration <10 days or other CDI treatment prior to FDX were excluded. Outcomes included recurrence within 2 months, global and clinical cure rates, and adverse events. Univariate and multivariate analyses were performed to evaluate efficacy. Results: Among 82 patients, the FDX + BEZ group (n = 30) demonstrated significantly higher global (86.7% vs. 65.4%; p < 0.05) and clinical cure rates (90.0% vs. 69.2%; p < 0.05) compared with the FDX-alone group (n = 52), despite more severe cases in the combination group. Recurrence rates were non-significantly lower in the FDX + BEZ group (3.3% vs. 11.5%). Combination therapy also accelerated diarrhea resolution without additional adverse events. Multivariate analysis identified FDX + BEZ as significantly associated with improved clinical cure (adjusted odds ratio 4.167; 95% CI: 1.029-16.885). Conclusions: FDX + BEZ therapy offers superior efficacy and safety in CDI patients with recurrence risk factors, presenting a promising strategy for optimizing CDI management.
推荐引用方式
GB/T 7714：

Hirai Jun,Mori Nobuaki,Hanai Yuki, et al. Evaluating Bezlotoxumab-Fidaxomicin Combination Therapy in Clostridioides Infection: A Single-Center Retrospective Study from Aichi Prefecture, Japan [J].ANTIBIOTICS-BASEL,2025,14(3).
APA：

Hirai Jun,Mori Nobuaki,Hanai Yuki,Asai Nobuhiro,&Mikamo Hiroshige.(2025).Evaluating Bezlotoxumab-Fidaxomicin Combination Therapy in Clostridioides Infection: A Single-Center Retrospective Study from Aichi Prefecture, Japan .ANTIBIOTICS-BASEL,14(3).
MLA：

Hirai Jun, et al. "Evaluating Bezlotoxumab-Fidaxomicin Combination Therapy in Clostridioides Infection: A Single-Center Retrospective Study from Aichi Prefecture, Japan" .ANTIBIOTICS-BASEL 14,3(2025).
数据来源自科睿唯安Web of Science核心合集
入库时间：

2025/5/14 12:07:58
更新时间：

2025/5/14 12:07:58

浏览次数：3  下载次数：0

分享到：

浏览次数：3

下载次数：0

打印次数：0